to discuss the current standard of care and the recent label expansion of Jardiance (empagliflozin) for the treatment for chronic kidney disease and type 2 diabetes.
This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second View: Discussing the recent label expansion of Jardiance (empagliflozin) to patients with Chronic kidney disease and type 2 diabetes
Ticker(s): LLYWho's the expert?
Institution: St. Luke's Hospital of Duluth
- Board certified in Internal medicine annd nephrology with an American Hypertension Specialist Certification(AHSC)
- Specializes in kidney transplantation and transplantation immunology while having close to 20 publications in the area involving kidney diseases
- treats close to 40 resistant hypertension patients per month
Interview Goal
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
